Arena Faces New FDA Worries Over Weight-Loss Drug

Law360, New York (May 8, 2012, 7:48 PM EDT) -- U.S. Food and Drug Administration drug reviewers said Tuesday that Arena Pharmaceuticals had eased concerns about potential cancer risks associated with its obesity drug lorcaserin, but said a high risk of heart valve disease could not be ruled out.

The reviewers provided the update in a 246-page briefing document ahead of a FDA advisory committee meeting Thursday to discuss the safety and efficacy of lorcaserin, a drug to help obese patients lose weight.

Lorcaserin was earlier linked to mammary gland tumors in both sexes in a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.